Navigation Links
CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
Date:5/16/2008

VIENNA, Va., May 16 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) reports financial results for the three and six months ended March 31, 2008.

Geert Kersten, Chief Executive Officer of CEL-SCI Corporation said, "We are completely focused on getting our cancer therapy Multikine(R) into its pivotal Phase III clinical trial. We were unable to start the Phase III study until the completion of our dedicated manufacturing facility for Multikine from which we can supply the Phase III study and subsequent sale of the drug. This facility is expected to be completed in the 3rd quarter of 2008. The Phase III study is designed to replicate the safety and efficacy results seen in the earlier studies and lead to an approval to sell Multikine."

Mr. Kersten continued, "Our financial results reflect our primary focus on the facility and preparation for the Phase III trial. Our Phase III trial is the first Phase III trial to test the theory that immune stimulation before surgery, radiation and/or chemotherapy will increase survival of cancer patients."

About Multikine:

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

CEL-SCI is currently building a manufacturing facility for Multikine close to Baltimore, MD. Upon completion of the facility in the 3rd quarter of 2008, CEL-SCI will commence the Phase III clinical trial. Multikine appears to be the first non-toxic cancer drug.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company's loss from operations for the quarter ended March 31, 2008 was $2,085,098 versus a loss from operations of $2,012,605 during the same quarter in 2007. The net loss per common share for the quarter ended March 31, 2008 was $0.03 which was unchanged from the same quarter in 2007. The Company's loss from operations for the six months ended March 31, 2008 was $4,952,536 versus a net loss from operations of $3,592,516 during the same six months in 2007. The Company's net loss per common share for the six months ended March 31, 2008 was $0.05 which was unchanged from the same six month period in 2007.

During the three month period ended March 31, 2008, research and development charges were $1,037,063 compared to $678,865 during the same period in 2007. During the six month period ended March 31, 2008, research and development expenses were $2,066,029 compared to $1,185,023 during the same period in 2007.

During the three month period ended March 31, 2008, general and administrative expenses were $968,820 compared to $1,316,146 during the same period in 2007. During the six month period ended March 31, 2008, general and administrative expenses were $2,754,569 compared to $2,368,850 during the same period in 2007.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.

CEL-SCI CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended

March 31,

2008 2007

REVENUE:

Grant revenue $- $17,917

Rent income - 6,805

Other income - -

Total Revenue - 24,722

EXPENSES:

Research and development, excluding

depreciation of $97,035 and

$20,832 included below 1,037,063 678,865

Depreciation and amortization 79,215 42,316

General and administrative 968,820 1,316,146

Total Expenses 2,085,098 2,037,327

LOSS FROM OPERATIONS (2,085,098) (2,012,605)

LOSS ON DERIVATIVE INSTRUMENTS (1,160,937) (447,356)

INTEREST INCOME 157,256 77,114

INTEREST EXPENSE (121,515) (341,038)

NET LOSS BEFORE INCOME TAXES 3,210,294) (2,723,885)

INCOME TAX PROVISION - -

NET LOSS $(3,210,294) $(2,723,885)

DIVIDENDS (424,815) -

NET LOSS AVAILABLE TO COMMON

SHAREHOLDERS $(3,635,109) $(2,723,885)

NET LOSS PER COMMON SHARE (BASIC) $(0.03) $(0.03)

NET LOSS PER COMMON SHARE (DILUTED) $(0.03) $(0.03)

WEIGHTED AVERAGE COMMON

SHARES OUTSTANDING 116,312,378 83,836,076

CEL-SCI CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

Six Months Ended

March 31,

2008 2007

REVENUE:

Grant revenue $- $31,779

Rent income 1,530 12,895

Other income - 841

Total Revenue 1,530 45,515

EXPENSES:

Research and development, excluding

depreciation of $97,856 and

$41,794 included below 2,066,029 1,185,023

Depreciation and amortization 133,468 84,158

General and administrative 2,754,569 2,368,850

Total Expenses 4,954,066 3,638,031

LOSS FROM OPERATIONS (4,952,536) (3,592,516)

GAIN (LOSS) ON DERIVATIVE INSTRUMENTS (170,949) 271,891

INTEREST INCOME 335,987 172,665

INTEREST EXPENSE (265,531) (688,284)

NET LOSS BEFORE INCOME TAXES (5,053,029) (3,836,244)

INCOME TAX PROVISION - -

NET LOSS $(5,053,029) $(3,836,244)

DIVIDENDS (424,815) -

NET LOSS AVAILABLE TO COMMON

SHAREHOLDERS $(5,477,844) $(3,836,244)

NET LOSS PER COMMON SHARE (BASIC) $(0.05) $(0.05)

NET LOSS PER COMMON SHARE (DILUTED) $(0.05) $(0.05)

WEIGHTED AVERAGE COMMON

SHARES OUTSTANDING 116,008,631 83,377,267


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
4. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
5. RediStat Corporation Partners With ALERT FM for Disaster-Proof Emergency Communications
6. Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008
7. Diagnostic Health Corporation Names Robert E. Gontarek as COO
8. AGA Medical Corporation Receives CE Mark Approval for the AMPLATZER(R) Vascular Plug III
9. Insulet Corporation to Present at the Seventh Annual JMP Securities Research Conference on May 20, 2008
10. Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference
11. CRH Medical Corporation opens Center in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
Breaking Medicine Technology: